NDA 215272 · Organon LLC
Vtama
Tapinarof · Topical · Aryl Hydrocarbon Receptor Agonist
NovelCDER novel approval, May 23, 2022: To treat plaque psoriasis
Last checked: Nov 20, 2026Latest source record: Dec 12, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2022
May 23, 2022
Approved uses
2
Original approval plus efficacy supplements
Registered trials
29
11 Phase 3, 0 recruiting
FAERS reports
1,974
205 serious, 6 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect May 28, 2025.
VTAMA cream, 1% is an aryl hydrocarbon receptor agonist indicated for: the topical treatment of plaque psoriasis in adults. ( 1.1 ) the topical treatment of atopic dermatitis in adults and pediatric patients 2 years of age and older. ( 1.2 ) 1.1 Plaque Psoriasis VTAMA ® cream is indicated for the topical treatment of plaque psoriasis in adults. 1.2 Atopic Dermatitis VTAMA cream is indicated for the topical treatment of atopic dermatitis in adults and pediatric patients 2 years of age and older.
Mechanism: Tapinarof is an aryl hydrocarbon receptor (AhR) agonist. The specific mechanisms by which VTAMA cream exerts its therapeutic actions are unknown.
Therapeutic areas: Immunology and inflammation
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Dec 12, 2024 Supplement 2 · Efficacy LetterLabel
- May 23, 2022 Original approval · Type 1 - New Molecular Entity NovelLetterLabelReview
1 products under this application
- VTAMA · TAPINAROF 1% · CREAM, TOPICAL · Prescription · TE TBD
Clinical trials
Interventional ClinicalTrials.gov studies with "Tapinarof" as an intervention, any sponsor and status, largest first.
- Phase IV Clinical Study of Benvitimod Cream in the Treatment of Mild to Moderate Psoriasis in AdultsStatus unknown
Peking University People's HospitalAcademic, hospital or other
NCT05064748 · 2,000 participants (planned) · Start Jun 1, 2021 · Primary completion Mar 31, 2024
Drug: Benvitimod · For: Psoriasis
Sites: Beijing, China
- Long Term Extension Study of Tapinarof for Plaque Psoriasis in Adults (3003)Pivotal-lookingCompleted
Organon and CoIndustry
NCT04053387 · 763 participants · Start Aug 13, 2019 · Primary completion Apr 6, 2021
Drug: tapinarof cream, 1% · For: Plaque Psoriasis
Sites: Birmingham, Alabama; Phoenix, Arizona; Bryant, Arkansas · 104 sites in all
- Long Term Extension Study of Tapinarof Cream, 1% for Subjects With Atopic DermatitisPivotal-lookingCompleted
Organon and CoIndustry
NCT05142774 · 728 participants · Start Oct 28, 2021 · Primary completion Feb 29, 2024
Drug: Tapinarof cream, 1% · For: Atopic Dermatitis
Sites: Birmingham, Alabama; Phoenix, Arizona; Scottsdale, Arizona · 112 sites in all
- A Study Comparing Tapinarof Cream 1% and Vtama® Cream 1% in the Treatment of Plaque Psoriasis.Pivotal-lookingCompleted
Sun Pharmaceutical Industries, Inc.Industry
NCT07546214 · 575 participants · Start Oct 13, 2025 · Primary completion Mar 18, 2026
Drug: Tapinarof Cream, 1%; Vtama® (Tapinarof) Cream, 1% and 1 more · For: Plaque Psoriasis
Sites: Hawthorne, New York
- Study Comparing Tapinarof Cream 1% To VTAMA ® (Tapinarof Cream 1%) In the Treatment of Plaque PsoriasisPivotal-lookingCompleted
Teva Pharmaceuticals USATeva (TEVA)
NCT06742957 · 560 participants · Start Dec 17, 2024 · Primary completion Oct 7, 2025
Drug: Tapinarof Cream 1%; VTAMA® and 1 more · For: Plaque Type Psorisis
Sites: Scottsdale, Arizona; Bryant, Arkansas; Dublin, California · 26 sites in all
- Tapinarof for the Treatment of Plaque Psoriasis in Adults (3002)Pivotal-lookingCompleted
Organon and CoIndustry
NCT03983980 · 515 participants · Start Jun 6, 2019 · Primary completion May 13, 2020
Drug: Tapinarof; Vehicle Cream · For: Plaque Psoriasis
Sites: Fort Smith, Arkansas; Fountain Valley, California; Fremont, California · 50 sites in all
- Tapinarof for the Treatment of Plaque Psoriasis in Adults (3001)Pivotal-lookingCompleted
Organon and CoIndustry
NCT03956355 · 510 participants · Start May 21, 2019 · Primary completion May 26, 2020
Drug: Tapinarof; Vehicle Cream · For: Plaque Psoriasis
Sites: Birmingham, Alabama; Phoenix, Arizona; Hot Springs, Arkansas · 53 sites in all
- Tapinarof for the Treatment of Atopic Dermatitis in Children and AdultsPivotal-lookingCompleted
Organon and CoIndustry
NCT05014568 · 407 participants · Start Sep 1, 2021 · Primary completion Mar 30, 2023
Drug: tapinarof cream, 1%; Vehicle cream · For: Atopic Dermatitis
Sites: Birmingham, Alabama; Phoenix, Arizona; Bryant, Arkansas · 67 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- folliculitis292
- pruritus238
- headache182
- rash152
- dermatitis contact134
- drug ineffective130
- erythema124
- skin burning sensation87
- psoriasis77
- application site erythema63
- off label use63
- application site pruritus62
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2019 | 1 |
| 2020 | 3 |
| 2021 | 4 |
| 2022 | 192 |
| 2023 | 664 |
| 2024 | 506 |
| 2025 | 263 |
| 2026 | 341 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Vtama (Tapinarof)
2024 spending
$26.7M
Beneficiaries
8,600
18,599 claims
Per beneficiary
$3,107
$23.01 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $0 |
| 2022 | $2,800,009 |
| 2023 | $18,812,197 |
| 2024 | $26,721,943 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Focused update: Guidelines of care for the management of atopic dermatitis in adults.
Davis DMR, Frazer-Green L, Alikhan A, et al. · J Am Acad Dermatol 2025 · Systematic Review, Practice Guideline
- Topical anti-inflammatory treatments for eczema: network meta-analysis.
Lax SJ, Van Vogt E, Candy B, et al. · Cochrane Database Syst Rev 2024 · Systematic Review, Network Meta-Analysis
- Tapinarof cream 1% once daily: Significant efficacy in the treatment of moderate to severe atopic dermatitis in adults and children down to 2 years of age in the pivotal phase 3 ADORING trials.
Silverberg JI, Eichenfield LF, Hebert AA, et al. · J Am Acad Dermatol 2024 · Clinical Trial, Phase III, Randomized Controlled Trial
- Phase 3 Trials of Tapinarof Cream for Plaque Psoriasis.
Lebwohl MG, Stein Gold L, Strober B, et al. · N Engl J Med 2021 · Clinical Trial, Phase III, Multicenter Study
- Tapinarof cream for the treatment of atopic dermatitis: Efficacy and safety results from two Japanese phase 3 trials.
Igarashi A, Tsuji G, Fukasawa S, et al. · J Dermatol 2024 · Clinical Trial, Phase III, Randomized Controlled Trial
- Skin clearance, duration of treatment-free interval, and safety of tapinarof cream 1% once daily: Results from ADORING 3, a 48-week phase 3 open-label extension trial in adults and children down to 2 years of age with atopic dermatitis.
Bissonnette R, Stein Gold L, Kircik L, et al. · J Am Acad Dermatol 2025 · Clinical Trial, Phase III, Multicenter Study
Sponsor: Organon LLC
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.